These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 10627178)

  • 41. Clinical application of PET for the evaluation of brain tumors.
    Coleman RE; Hoffman JM; Hanson MW; Sostman HD; Schold SC
    J Nucl Med; 1991 Apr; 32(4):616-22. PubMed ID: 2013802
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma.
    Delbeke D
    J Nucl Med; 1999 Apr; 40(4):591-603. PubMed ID: 10210218
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Brain imaging of glucose utilization in cerebral tumors.
    Di Chiro G
    Res Publ Assoc Res Nerv Ment Dis; 1985; 63():185-97. PubMed ID: 3875134
    [No Abstract]   [Full Text] [Related]  

  • 44. Relation between tissue nature and (18F) fluorodeoxyglucose kinetics evaluated by dynamic positron emission tomography in human brain tumors.
    Yamaguchi T; Sasaki H; Ogawa T; Mineura K; Uemura K; Kanno I; Shishido F; Murakami M; Inugami A; Higano S
    Acta Radiol Suppl; 1986; 369():415-8. PubMed ID: 2980513
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis.
    Yamada Y; Uchida Y; Tatsumi K; Yamaguchi T; Kimura H; Kitahara H; Kuriyama T
    J Nucl Med; 1998 Jul; 39(7):1160-6. PubMed ID: 9669387
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain.
    Patronas NJ; Di Chiro G; Brooks RA; DeLaPaz RL; Kornblith PL; Smith BH; Rizzoli HV; Kessler RM; Manning RG; Channing M; Wolf AP; O'Connor CM
    Radiology; 1982 Sep; 144(4):885-9. PubMed ID: 6981123
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of thallium-201 SPECT to quantitate malignancy grade of gliomas.
    Black KL; Hawkins RA; Kim KT; Becker DP; Lerner C; Marciano D
    J Neurosurg; 1989 Sep; 71(3):342-6. PubMed ID: 2549223
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PET-FDG of pleomorphic xanthoastrocytoma.
    Bicik I; Raman R; Knightly JJ; Di Chiro G; Fulham MJ
    J Nucl Med; 1995 Jan; 36(1):97-9. PubMed ID: 7799091
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome.
    Valk PE; Budinger TF; Levin VA; Silver P; Gutin PH; Doyle WK
    J Neurosurg; 1988 Dec; 69(6):830-8. PubMed ID: 2848111
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Positron-emission tomography in the diagnosis of space-occupying formations of the brain].
    Medvedev SV; Bekhtereva NP; Kostenikov NA; Rudas MS; Korotkov AD; Kataeva GV; Korsakov MV; Gurchin FA; Mozhaev SV; Fadeev NP
    Zh Vopr Neirokhir Im N N Burdenko; 1996; (1):21-6. PubMed ID: 8711965
    [No Abstract]   [Full Text] [Related]  

  • 51. Effect of barbiturate coma on glucose utilization in normal brain versus gliomas. Positron emission tomography studies.
    Blacklock JB; Oldfield EH; Di Chiro G; Tran D; Theodore W; Wright DC; Larson SM
    J Neurosurg; 1987 Jul; 67(1):71-5. PubMed ID: 3496428
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PET imaging I.
    Alavi A
    Radiol Clin North Am; 2004 Nov; 42(6):xi-xiii. PubMed ID: 15488552
    [No Abstract]   [Full Text] [Related]  

  • 53. Clinical evaluation of a high-resolution (2.6-mm) positron emission tomography.
    Valk PE; Jagust WJ; Derenzo SE; Huesman RH; Geyer AB; Budinger TF
    Radiology; 1990 Sep; 176(3):783-90. PubMed ID: 2389037
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Functional imaging using PET and SPECT in pediatric neurology.
    Messa C; Grana C; Lucignani G; Fazio F
    J Nucl Biol Med (1991); 1994 Mar; 38(1):85-8. PubMed ID: 8075181
    [No Abstract]   [Full Text] [Related]  

  • 55. PET quantitation: blessing and curse.
    Di Chiro G; Brooks RA
    J Nucl Med; 1988 Sep; 29(9):1603-4. PubMed ID: 3261788
    [No Abstract]   [Full Text] [Related]  

  • 56. Amino acid PET and clinical management of glioma patients.
    Herholz K
    Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):683-4. PubMed ID: 20107786
    [No Abstract]   [Full Text] [Related]  

  • 57. [Cerebral positron emission tomography with F18-fluorodeoxyglucose].
    Grupo PET de la SEMN.
    Rev Esp Med Nucl; 2002 Feb; 21(1):38-40. PubMed ID: 11821002
    [No Abstract]   [Full Text] [Related]  

  • 58. Positron emission tomography in clinical practice.
    Alagona P; Eikman EA; Cacciatore R; Zangara L
    J Fla Med Assoc; 1992 Jul; 79(7):453-8. PubMed ID: 1500922
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas.
    Rhodes CG; Wise RJ; Gibbs JM; Frackowiak RS; Hatazawa J; Palmer AJ; Thomas DG; Jones T
    Ann Neurol; 1983 Dec; 14(6):614-26. PubMed ID: 6606389
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma.
    Barker FG; Chang SM; Valk PE; Pounds TR; Prados MD
    Cancer; 1997 Jan; 79(1):115-26. PubMed ID: 8988735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.